Literature DB >> 14533133

Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996-2002.

F Schifano1, A Oyefeso, J Corkery, K Cobain, R Jambert-Gray, G Martinotti, A H Ghodse.   

Abstract

The present study reports on all deaths related to taking ecstasy (alone, or in a polydrug combination) occurring in England and Wales in the time frame August 1996-April 2002. Data presented here are based on all information recorded in the National Programme on Substance Abuse Deaths (np-SAD) database. The np-SAD regularly receives all information on drug related deaths in addicts and non addicts from coroners. A total of 202 ecstasy-related fatalities occurred in the chosen time-frame, showing a steady increase in the number of deaths each year. The ratio male:female was 4:1 and 3 of 4 victims were younger than 29. In 17% of cases ecstasy was the sole drug implicated in death and in the remaining cases a number of other drugs (mostly alcohol, cocaine, amphetamines and opiates) have been found. According to toxicology results, MDMA accounted for 86% of cases and MDA for 13% of cases; single deaths were associated with MDEA and PMA. This is the largest sample of ecstasy related deaths so far; possible explanations are given for the observed steady increase in ecstasy-related deaths and a tentative 'rationale' for this polypharmacy combination is then proposed. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14533133     DOI: 10.1002/hup.528

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  13 in total

Review 1.  Using administrative data for longitudinal substance abuse research.

Authors:  Elizabeth Evans; Christine E Grella; Debra A Murphy; Yih-Ing Hser
Journal:  J Behav Health Serv Res       Date:  2008-08-05       Impact factor: 1.505

2.  Poly-Drug Use among Ecstasy Users: Separate, Synergistic, and Indiscriminate Patterns.

Authors:  M Boeri; C Sterk; M Bahora; K Elifson
Journal:  J Drug Issues       Date:  2008-04

Review 3.  A developmental comparison of the neurobehavioral effects of ecstasy (MDMA).

Authors:  Brian J Piper
Journal:  Neurotoxicol Teratol       Date:  2006-10-20       Impact factor: 3.763

Review 4.  Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA).

Authors:  J R Docherty
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

Review 5.  A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities.

Authors:  Fabrizio Schifano
Journal:  Psychopharmacology (Berl)       Date:  2003-12-13       Impact factor: 4.530

6.  Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths.

Authors:  Li-Tzy Wu; William E Schlenger; Deborah M Galvin
Journal:  Drug Alcohol Depend       Date:  2006-02-17       Impact factor: 4.492

7.  Hallucinogen-related disorders in a national sample of adolescents: the influence of ecstasy/MDMA use.

Authors:  Li-Tzy Wu; Christopher L Ringwalt; Roger D Weiss; Dan G Blazer
Journal:  Drug Alcohol Depend       Date:  2009-06-04       Impact factor: 4.492

8.  Hallucinogen use disorders among adult users of MDMA and other hallucinogens.

Authors:  Li-Tzy Wu; Christopher L Ringwalt; Paolo Mannelli; Ashwin A Patkar
Journal:  Am J Addict       Date:  2008 Sep-Oct

9.  Use of ecstasy and other psychoactive substances among school-attending adolescents in Taiwan: national surveys 2004-2006.

Authors:  Wei J Chen; Tsung-Chieh Fu; Te-Tien Ting; Wei-Lun Huang; Guang-Mang Tang; Chuhsing Kate Hsiao; Chuan-Yu Chen
Journal:  BMC Public Health       Date:  2009-01-21       Impact factor: 3.295

Review 10.  Fatal and non-fatal health incidents related to recreational ecstasy use.

Authors:  Jan van Amsterdam; Ed Pennings; Wim van den Brink
Journal:  J Psychopharmacol       Date:  2020-01-07       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.